{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:58:41Z","timestamp":1774893521962,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Aurinia Pharmaceuticals Inc"},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK 124549"],"award-info":[{"award-number":["DK 124549"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK 095059"],"award-info":[{"award-number":["DK 095059"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04837-w","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:15:33Z","timestamp":1771917333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Yu","family":"Kamigaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda P.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn J.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Rehaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Biederman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zackary S.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"2","key":"4837_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dialysis Transplantation. 2010;26(2):414\u201330.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"24","key":"4837_CR2","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJM198506133122404","volume":"312","author":"GB Appel","year":"1985","unstructured":"Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med. 1985;312(24):1544\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"4837_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1523-1755.2005.00524.x","volume":"68","author":"JS Kim","year":"2005","unstructured":"Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int. 2005;68(3):1275\u201381.","journal-title":"Kidney Int"},{"issue":"11","key":"4837_CR4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00467-009-1282-y","volume":"24","author":"N MacHardy","year":"2009","unstructured":"MacHardy N, Miles PV, Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2193\u2013201.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4837_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"issue":"8","key":"4837_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529\u201361.","journal-title":"Pediatr Nephrol"},{"key":"4837_CR7","first-page":"11","volume":"2019","author":"ID Liu","year":"2019","unstructured":"Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2019;2019:11.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"4837_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","volume":"2","author":"K Tullus","year":"2018","unstructured":"Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"4837_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219\u201331.","journal-title":"Kidney Int"},{"issue":"10289","key":"4837_CR10","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u201380.","journal-title":"Lancet"},{"issue":"1","key":"4837_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillan AEZ, Levchenko O, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024;76(1):59\u201367.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"4837_CR12","doi-asserted-by":"publisher","first-page":"F213","DOI":"10.1152\/ajprenal.90421.2008","volume":"296","author":"JW Pippin","year":"2009","unstructured":"Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiology-Renal Physiol. 2009;296(2):F213\u201329.","journal-title":"Am J Physiology-Renal Physiol"},{"issue":"15","key":"4837_CR13","doi-asserted-by":"publisher","first-page":"e14515","DOI":"10.14814\/phy2.14515","volume":"8","author":"AP Waller","year":"2020","unstructured":"Waller AP, Agrawal S, Wolfgang KJ, Kino J, Chanley MA, Smoyer WE, et al. Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. Physiol Rep. 2020;8(15):e14515.","journal-title":"Physiol Rep"},{"issue":"7","key":"4837_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/ndt\/gfad254","volume":"39","author":"E Stamellou","year":"2024","unstructured":"Stamellou E, Agrawal S, Siegerist F, Buse M, Kuppe C, Lange T, et al. Inhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species. Nephrol Dial Transpl. 2024;39(7):1181\u201393.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4837_CR15","doi-asserted-by":"publisher","first-page":"108631","DOI":"10.1016\/j.isci.2023.108631","volume":"27","author":"S Bhayana","year":"2024","unstructured":"Bhayana S, Dougherty JA, Kamigaki Y, Agrawal S, Wijeratne S, Fitch J, et al. Glucocorticoid- and pioglitazone-induced proteinuria reduction in experimental NS both correlate with glomerular ECM modulation. iScience. 2024;27(1):108631.","journal-title":"iScience"},{"issue":"4","key":"4837_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ki.1975.105","volume":"8","author":"GB Ryan","year":"1975","unstructured":"Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney Int. 1975;8(4):219\u201332.","journal-title":"Kidney Int"},{"issue":"9","key":"4837_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931\u20138.","journal-title":"Nat Med"},{"key":"4837_CR18","doi-asserted-by":"publisher","first-page":"32087","DOI":"10.1038\/srep32087","volume":"6","author":"X Shen","year":"2016","unstructured":"Shen X, Jiang H, Ying M, Xie Z, Li X, Wang H, et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep. 2016;6:32087.","journal-title":"Sci Rep"},{"issue":"3","key":"4837_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/path.5512","volume":"252","author":"X Shen","year":"2020","unstructured":"Shen X, Zhang Y, Lin C, Weng C, Wang Y, Feng S, et al. Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway. J Pathol. 2020;252(3):227\u201338.","journal-title":"J Pathol"},{"key":"4837_CR20","unstructured":"U.S. Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville (MD): Center for Drug Evaluation and Research (CDER), Office of New Drugs; 2005."},{"issue":"12","key":"4837_CR21","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1681\/ASN.2014111097","volume":"26","author":"BA Kerlin","year":"2015","unstructured":"Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE. Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome. J Am Soc Nephrol. 2015;26(12):3009\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"4837_CR22","doi-asserted-by":"crossref","unstructured":"Sharma R, Waller AP, Agrawal S, Wolfgang KJ, Luu H, Shahzad K, et al. Thrombin-induced podocyte injury is protease-activated receptor dependent. J Am Soc Nephrol. 2017;28(9).","DOI":"10.1681\/ASN.2016070789"},{"key":"4837_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.thromres.2021.02.007","volume":"201","author":"AP Waller","year":"2021","unstructured":"Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, et al. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021;201:50\u20139.","journal-title":"Thromb Res"},{"issue":"12","key":"4837_CR24","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1172\/JCI118723","volume":"97","author":"WE Smoyer","year":"1996","unstructured":"Smoyer WE, Gupta A, Mundel P, Ballew JD, Welsh MJ. Altered expression of glomerular heat shock protein 27 in experimental nephrotic syndrome. J Clin Invest. 1996;97(12):2697\u2013704.","journal-title":"J Clin Invest"},{"issue":"5","key":"4837_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ijantimicag.2017.01.015","volume":"49","author":"C Kader","year":"2017","unstructured":"Kader C, Sunbul M, Das YK, Yarim M, Bedir A, Karaca E, et al. Telbivudine attenuates gentamicin-induced kidney injury in rats. Int J Antimicrob Agents. 2017;49(5):595\u2013602.","journal-title":"Int J Antimicrob Agents"},{"key":"4837_CR26","doi-asserted-by":"crossref","unstructured":"Ozer A, Sengel N, Kucuk A, Yigman Z, Ozdemir C, Kilic Y, et al. The effect of cerium oxide (CeO(2)) on ischemia-reperfusion injury in skeletal muscle in mice with streptozocin-induced diabetes. Med (Kaunas). 2024;60(5).","DOI":"10.3390\/medicina60050752"},{"key":"4837_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.avsg.2020.06.050","volume":"69","author":"E Ak","year":"2020","unstructured":"Ak E, Ak K, Ustandag UV, Kervancioglu-Demirci E, Emekli-Alturfan E, Cetinel S. Milrinone attenuates heart and lung remote injury after abdominal aortic cross-clamping. Ann Vasc Surg. 2020;69:391\u20139.","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"4837_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12871-025-03373-8","volume":"25","author":"F Aktepe","year":"2025","unstructured":"Aktepe F, Kip G, Erel S, Kucuk A, Arslan M, Sezen SC, et al. The effect of dexmedetomidine on remote organ injury in the lung in rats with pancreatic ischemia reperfusion model. BMC Anesthesiol. 2025;25(1):504.","journal-title":"BMC Anesthesiol"},{"issue":"5","key":"4837_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","volume":"5","author":"M Sampson","year":"2020","unstructured":"Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540\u20138.","journal-title":"JAMA Cardiol"},{"key":"4837_CR30","doi-asserted-by":"publisher","first-page":"117364","DOI":"10.1016\/j.atherosclerosis.2023.117364","volume":"386","author":"R Zubiran","year":"2023","unstructured":"Zubiran R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, Martagon-Rosado A, Sampson M, et al. Performance of the enhanced sampson-NIH equation for VLDL-C and LDL-C in a population with Familial combined hyperlipidemia. Atherosclerosis. 2023;386:117364.","journal-title":"Atherosclerosis"},{"key":"4837_CR31","doi-asserted-by":"crossref","unstructured":"Waller AP, Wolfgang KJ, Pruner I, Stevenson ZS, Abdelghani E, Muralidharan K, et al. Effects of prothrombin on podocytopathy and proteinuria in glomerular disease. J Am Soc Nephrol. 2025.","DOI":"10.1681\/ASN.0000000676"},{"issue":"3","key":"4837_CR32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1681\/ASN.V133630","volume":"13","author":"MA Saleem","year":"2002","unstructured":"Saleem MA, O\u2019Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13(3):630\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"4837_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/IJGM.S102819","volume":"9","author":"DG Levitt","year":"2016","unstructured":"Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and Gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229\u201355.","journal-title":"Int J Gen Med"},{"issue":"1","key":"4837_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ki.1988.3","volume":"33","author":"AA Eddy","year":"1988","unstructured":"Eddy AA, Michael AF. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int. 1988;33(1):14\u201323.","journal-title":"Kidney Int"},{"issue":"5","key":"4837_CR35","first-page":"1111","volume":"138","author":"AA Eddy","year":"1991","unstructured":"Eddy AA, McCulloch L, Liu E, Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol. 1991;138(5):1111\u201323.","journal-title":"Am J Pathol"},{"issue":"2","key":"4837_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5049\/EBP.2020.18.2.31","volume":"18","author":"CH Jo","year":"2020","unstructured":"Jo CH, Kim S, Kim GH. Association of proteinuria with urinary concentration defect in puromycin aminonucleoside nephrosis. Electrolyte Blood Press. 2020;18(2):31\u20139.","journal-title":"Electrolyte Blood Press"},{"issue":"1\u20132","key":"4837_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.etp.2010.06.004","volume":"64","author":"A Herrmann","year":"2012","unstructured":"Herrmann A, Tozzo E, Funk J. Semi-automated quantitative image analysis of podocyte desmin immunoreactivity as a sensitive marker for acute glomerular damage in the rat puromycin aminonucleoside nephrosis (PAN) model. Exp Toxicol Pathol. 2012;64(1\u20132):45\u20139.","journal-title":"Exp Toxicol Pathol"},{"issue":"10141","key":"4837_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61\u201374.","journal-title":"Lancet"},{"key":"4837_CR39","doi-asserted-by":"crossref","unstructured":"Kockx M, Kritharides L. Cyclosporin A-induced dyslipidemia and LDL receptors. In: Patel VB, editor. The molecular nutrition of fats. Academic Press; 2019:323\u2013333","DOI":"10.1016\/B978-0-12-811297-7.00025-1"},{"issue":"10","key":"4837_CR40","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/ndt\/gfr136","volume":"26","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND, Gollapudi P, Han S, Farahmand G, Yuan J, Rahimi A, et al. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL Docking receptor. Nephrol Dialysis Transplantation. 2011;26(10):3118\u201323.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"1","key":"4837_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41\u201352.","journal-title":"Kidney Int"},{"issue":"6","key":"4837_CR42","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/ndt\/13.6.1446","volume":"13","author":"MV Pahl","year":"1998","unstructured":"Pahl MV, Oveisi F, Khamiseh G, Vaziri ND. Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome. Nephrol Dial Transpl. 1998;13(6):1446\u201351.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4837_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","volume":"56","author":"K Liang","year":"1999","unstructured":"Liang K, Vaziri ND. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int. 1999;56(2):621\u20136.","journal-title":"Kidney Int"},{"issue":"4","key":"4837_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0022-2143(97)90038-X","volume":"130","author":"K Liang","year":"1997","unstructured":"Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med. 1997;130(4):387\u201394.","journal-title":"J Lab Clin Med"},{"issue":"4","key":"4837_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11892-009-0047-0","volume":"9","author":"S Badiou","year":"2009","unstructured":"Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diab Rep. 2009;9(4):305\u201311.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"4837_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pharmthera.2010.06.001","volume":"128","author":"M Kockx","year":"2010","unstructured":"Kockx M, Jessup W, Kritharides L. Cyclosporin A and atherosclerosis \u2014 cellular pathways in atherogenesis. Pharmacol Ther. 2010;128(1):106\u201318.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"4837_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.mce.2012.10.030","volume":"365","author":"MJ Pereira","year":"2013","unstructured":"Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, et al. The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. Mol Cell Endocrinol. 2013;365(2):260\u20139.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"4837_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"4837_CR49","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","volume":"11","author":"S Busque","year":"2011","unstructured":"Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation. Am J Transpl. 2011;11(12):2675\u201384.","journal-title":"Am J Transpl"},{"issue":"2","key":"4837_CR50","first-page":"246","volume":"5","author":"S Han","year":"2013","unstructured":"Han S, Vaziri ND, Gollapudi P, Kwok V, Moradi H. Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome. Am J Transl Res. 2013;5(2):246\u201353.","journal-title":"Am J Transl Res"},{"issue":"10","key":"4837_CR51","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.metabol.2007.05.007","volume":"56","author":"CH Kim","year":"2007","unstructured":"Kim CH, Kim HJ, Mitsuhashi M, Vaziri ND. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome. Metabolism. 2007;56(10):1377\u201382.","journal-title":"Metabolism"},{"issue":"6","key":"4837_CR52","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/ki.1997.242","volume":"51","author":"K Liang","year":"1997","unstructured":"Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 1997;51(6):1761\u20135.","journal-title":"Kidney Int"},{"issue":"3","key":"4837_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ki.1996.388","volume":"50","author":"ND Vaziri","year":"1996","unstructured":"Vaziri ND, Liang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int. 1996;50(3):887\u201393.","journal-title":"Kidney Int"},{"issue":"6","key":"4837_CR54","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/ki.1997.263","volume":"51","author":"K Liang","year":"1997","unstructured":"Liang K, Vaziri ND. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997;51(6):1933\u20137.","journal-title":"Kidney Int"},{"issue":"5","key":"4837_CR55","doi-asserted-by":"publisher","first-page":"F823","DOI":"10.1152\/ajprenal.2001.280.5.F823","volume":"280","author":"ND Vaziri","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Ren Physiol. 2001;280(5):F823\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"4837_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/01.CIR.0000136023.70841.0F","volume":"110","author":"ND Vaziri","year":"2004","unstructured":"Vaziri ND, Liang KH. Acyl-coenzyme a:cholesterol acyltransferase Inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome. Circulation. 2004;110(4):419\u201325.","journal-title":"Circulation"},{"issue":"5","key":"4837_CR57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","volume":"15","author":"T van Gelder","year":"2022","unstructured":"van Gelder T, Lerma E, Engelke K, Huizinga RB. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol. 2022;15(5):515\u201329.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4837_CR58","doi-asserted-by":"crossref","unstructured":"Wakamatsu A, Fukusumi Y, Hasegawa E, Tomita M, Watanabe T, Narita I, et al. Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. Physiol Rep. 2016;4(6).","DOI":"10.14814\/phy2.12679"},{"issue":"4","key":"4837_CR59","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3109\/0886022X.2016.1148936","volume":"38","author":"Y Wen","year":"2016","unstructured":"Wen Y, Liu L, Zhou P, Li H, Wang Z, Zhang Y, et al. Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5\/6 nephrectomized rats. Ren Fail. 2016;38(4):564\u201370.","journal-title":"Ren Fail"},{"issue":"5","key":"4837_CR60","doi-asserted-by":"publisher","first-page":"e0155504","DOI":"10.1371\/journal.pone.0155504","volume":"11","author":"F Ding","year":"2016","unstructured":"Ding F, Li X, Li B, Guo J, Zhang Y, Ding J. Calpain-mediated cleavage of calcineurin in puromycin aminonucleoside-induced podocyte injury. PLoS ONE. 2016;11(5):e0155504.","journal-title":"PLoS ONE"},{"issue":"8","key":"4837_CR61","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/1535370214530365","volume":"239","author":"X Li","year":"2014","unstructured":"Li X, Zhang X, Li X, Wang X, Wang S, Ding J. Cyclosporine A protects podocytes via stabilization of cofilin-1 expression in the unphosphorylated state. Exp Biol Med (Maywood). 2014;239(8):922\u201336.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"4837_CR62","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/ndt\/gfv015","volume":"30","author":"N Guan","year":"2015","unstructured":"Guan N, Ren YL, Liu XY, Zhang Y, Pei P, Zhu SN, et al. Protective role of cyclosporine A and Minocycline on mitochondrial disequilibrium-related podocyte injury and proteinuria occurrence induced by adriamycin. Nephrol Dial Transpl. 2015;30(6):957\u201369.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"4837_CR63","doi-asserted-by":"publisher","first-page":"e21983","DOI":"10.1096\/fj.202101052R","volume":"35","author":"H Yasuda","year":"2021","unstructured":"Yasuda H, Fukusumi Y, Ivanov V, Zhang Y, Kawachi H. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. FASEB J. 2021;35(11):e21983.","journal-title":"FASEB J"},{"issue":"1","key":"4837_CR64","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000539700","volume":"49","author":"X Li","year":"2024","unstructured":"Li X, Ding F, Zhang X, Li X, Ding J. Cyclosporine a protects podocytes by regulating transgelin in adriamycin-induced podocyte injury. Kidney Blood Press Res. 2024;49(1):605\u201318.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"4837_CR65","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3181\/00379727-89-21833","volume":"89","author":"S Frenk","year":"1955","unstructured":"Frenk S, Antonowicz I, Craig JM, Metcoff J. Experimental nephrotic syndrome induced in rats by aminonucleoside; renal lesions and body electrolyte composition. Proc Soc Exp Biol Med. 1955;89(3):424\u20137.","journal-title":"Proc Soc Exp Biol Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04837-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:02:35Z","timestamp":1774890155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04837-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4837"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04837-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies and procedures were approved by the Nationwide Children\u2019s Hospital Institutional Animal Care and Use Committee (protocol AR21-00064) and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WES is on the Board of Directors of NephCure and receives no compensation as a board member. SZ, LMR, and JLC are employees and shareholders of Aurinia Pharmaceuticals Inc. All other authors have no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}